Study suggests new antibody therapy for tick-borne disease

Source Summary

Researchers have identified a potential antibody therapy for Crimean-Congo hemorrhagic fever (CCHF), a tick-borne viral disease with a fatality rate of up to 40%. CCHF currently lacks widely approved, highly effective treatments or vaccines and has been spreading into new regions worldwide.